Cingulate Inc. (CING)

Market Cap	20.74M
Revenue (ttm)	n/a
Net Income (ttm)	-17.96M
Shares Out	5.61M
EPS (ttm)	-5.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	488,612
Open	3.830
Previous Close	3.930
Day's Range	3.620 - 3.930
52-Week Range	3.020 - 6.010
Beta	-0.77
Analysts	Strong Buy
Price Target	31.00 (+737.84%)
Earnings Date	Nov 6, 2025

About CING

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 8, 2021
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: CING
• Website: https://www.cingulate.com

Analyst Summary

According to 4 analysts, the average rating for CING stock is "Strong Buy." The 12-month stock price target is $31.0, which is an increase of 737.84% from the latest price.

Price Target

$31.0

(737.84% upside)

Analyst Consensus: Strong Buy